With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
A phase 2 trial published last week in JCO reports outcomes for post-mastectomy radiation of 3.33 Gy x 11 fractions +/- 3.33 Gy x 4 scar boost. And get this: regional nodes were included, although internal mammary coverage was at the discretion of the treating physician. Grade 2 skin toxicity was 18% and there were no grade ≥3 toxicities. Most complications were related to reconstruction, and most of those were from infection. The same group has reported this regimen in the post-lumpectomy setting with slightly more skin toxicity and fibrosis. Notwithstanding missing details on internal mammary coverage and lung/heart dosimetry, this could represent an even more convenient breast radiation regimen. Canadians, look out.